WooGeneB&GCO
우진비앤지 · 018620
Health Care Pharmaceuticals · KOSDAQ
Market cap US$12.8M (₩17.7B)
Overview
WooGeneB&GCO supplies medicines and health products for livestock and companion animals, including antibiotics, nutritional supplements, disinfectants, microbial preparations, and vaccines, to distributors, direct corporate customers, and government agencies across South Korea.
It also produces active pharmaceutical ingredients for human use. Listed on KOSDAQ, Korea's tech and small-cap board, the company distributes through dealer networks, direct supply channels, and the Korea Public Procurement Service. A meaningful share of its revenue comes from exports, making international markets a significant part of its business alongside domestic sales.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$42M
- FY2024US$40.3M
- FY2025US$39.7M
Operating profit
- FY2023US$517.1K
- FY2024US$213.9K
- FY2025US$231.3K
Net income
- FY2023−US$860K
- FY2024−US$2.8M
- FY2025−US$2.6M
Key ratios (FY2025)
Why it matters
WooGeneB&GCO has two subsidiaries, OSP and BowWow Korea, that operate in the premium pet food and companion-animal treat segments, broadening the group beyond its core veterinary pharmaceuticals business.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?